RxDoctor Payments Data

Kimberly Sullivan, APRN

Family · Poteau, OKNPI 1639837099

Payments from drug & device makers

$246in general payments, 2019–2025

Across 13 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$61
  • GSK$60
  • AbbVie$32
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$21
  • Pfizer$20
  • Novo Nordisk$19
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$246100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$246 in reported general payments places this provider in the 45th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$33,630
Medicare patients
102
Services billed
629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide54$57,913
VraylarCariprazine Hcl27$40,999
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$32,216
OzempicSemaglutide18$22,887
RybelsusSemaglutide17$15,430
EliquisApixaban11$12,586
TrintellixVortioxetine Hydrobromide14$7,823
MyrbetriqMirabegron11$5,141
SymbicortBudesonide/Formoterol Fumarate16$3,748
Dexlansoprazole DrDexlansoprazole14$2,462
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,417
Gabapentin116$2,335
Lidocaine13$2,129
Duloxetine Hcl58$1,751
Buspirone Hcl38$1,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$61$57,91354 claims
AbbVieVraylar$32$40,99927 claims
Novo NordiskOzempic, Rybelsus$19$38,31735 claims
GSKTrelegy Ellipta$60$32,21636 claims
PfizerEliquis$20$12,58611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,026 family providers in Oklahoma.

Other family in Poteau

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →